miR-128 Inhibitory Nucleic Acids for Metabolic Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate cholesterol/lipid homeostasis and insulin sensitivity, contributing to metabolic syndrome, cardiovascular disease, and type 2 diabetes, as evidenced by dysregulation of key proteins such as LDLR, ABCA1, SIR1, and IRS1 by miR-128-1.
Innovation Solution
Administration of inhibitory nucleic acids, such as antisense oligonucleotides or antagomirs, complementary to miR-128-1, to target and downregulate its activity, thereby increasing expression of LDLR, ABCA1, SIR1, and IRS1, improving cholesterol/lipid metabolism and insulin signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If miR-128-1 is active, then cholesterol/lipid homeostasis is dysregulated and insulin resistance increases, but current methods cannot effectively regulate these pathways
Solution Approach 1:
The patent extracts and targets miR-128-1 specifically using inhibitory nucleic acids (antisense oligonucleotides, antagomirs) to separate its harmful effects from the rest of the biological system. By isolating and suppressing only this specific microRNA, the invention restores cholesterol/lipid homeostasis and insulin sensitivity without affecting other regulatory pathways.
Solution Approach 2:
The invention changes the expression level parameter of miR-128-1 from elevated/dysregulated to normalized levels through pharmacological intervention. This parameter change subsequently restores proper expression of target genes (LDLR, ABCA1, SIR1, IRS1) and improves metabolic parameters including cholesterol levels, triglycerides, and insulin sensitivity.
2Reliability
If inhibitory nucleic acids are administered to target miR-128-1, then cholesterol/lipid homeostasis is normalized and insulin resistance decreases, but the complexity of therapeutic intervention increases
Solution Approach 1:
The patent uses inhibitory nucleic acids as intermediary molecules that mediate between the external therapeutic agent and the internal miR-128-1 target. These nucleic acid-based intermediaries bind to miR-128-1 and prevent its function, thereby restoring insulin sensitivity and cholesterol homeostasis through a specific molecular mechanism.
Solution Approach 2:
The invention employs a universal approach where a single target (miR-128-1) controls multiple downstream effectors (LDLR, ABCA1, SIR1, IRS1) involved in different metabolic pathways. By suppressing one master regulator, the therapy simultaneously improves cholesterol/lipid metabolism and insulin signaling, achieving multi-functional therapeutic effects.
3Quantity of substance
If miR-128-1 levels are reduced, then expression of LDLR, ABCA1, SIR1, and IRS1 increases, but serum LDL and triglycerides may be affected
Solution Approach 1:
The patent implements a feedback mechanism where the reduction of miR-128-1 leads to increased expression of its target genes (LDLR, ABCA1, SIR1, IRS1), which in turn regulates serum lipid levels. The therapy monitors and adjusts to achieve the desired balance between protein expression and serum lipid profile, ensuring precise control.
Solution Approach 2:
The invention applies partial action by targeting only the specific region of miR-128-1 that mediates harmful effects, rather than completely eliminating all miR-128-1 function. This controlled suppression allows restoration of beneficial target gene expression while maintaining appropriate serum lipid levels through regulated protein synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces serum LDL and triglycerides, increases HDL, decreases obesity and insulin resistance, and treats conditions like non-alcoholic fatty liver disease and atherosclerosis by normalizing cholesterol/lipid homeostasis and enhancing insulin sensitivity.
Implementation Method 1
administering to the subject a therapeutically effective amount of an inhibitory nucleic acid that is complementary to all or part of any of SEQ ID NOs: 1-6
Data Source
AI summary
Methods for targeting microRNA 128 (miR-128) for regulating cholesterol/lipid metabolism and insulin sensitivity.